 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and subgroup analyses from the Companys robust lung cancer program will be presented at the European Society for Medical Oncology ESMO Congress 2021. We continue to make meaningful progress with our deep immuno-oncology portfolio, including our lung cancer program 